Literature DB >> 28742748

Beyond the PSA test: How to better stratify a patient's risk of prostate cancer.

Ryan Lewis1, Brad Hornberger.   

Abstract

The primary method of screening for and detecting prostate cancer is the prostate-specific antigen (PSA) test. Although this test is very prostate-specific, it is not cancer-specific; conditions other than prostate cancer can cause an elevated PSA. Many efforts have been made to discover more specific tests and methods beyond the PSA. This article describes several literature-supported tests and methods to better stratify a man's risk of having prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28742748     DOI: 10.1097/01.JAA.0000521148.78442.d5

Source DB:  PubMed          Journal:  JAAPA        ISSN: 0893-7400


  2 in total

1.  Ginger Phytochemicals Inhibit Cell Growth and Modulate Drug Resistance Factors in Docetaxel Resistant Prostate Cancer Cell.

Authors:  Chi-Ming Liu; Chiu-Li Kao; Yu-Ting Tseng; Yi-Ching Lo; Chung-Yi Chen
Journal:  Molecules       Date:  2017-09-05       Impact factor: 4.411

2.  Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer.

Authors:  Wieke C H Visser; Hans de Jong; Sandra Steyaert; Willem J G Melchers; Peter F A Mulders; Jack A Schalken
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-07-09       Impact factor: 5.455

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.